PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 1933338
PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 1933338
Exocrine Pancreatic Insufficiency Therapeutics Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
Growth Factors of exocrine pancreatic insufficiency (EPI) therapeutics Market
The global exocrine pancreatic insufficiency (EPI) therapeutics market is witnessing steady growth due to the rising prevalence of pancreatic disorders and increasing awareness of gastrointestinal health. Exocrine pancreatic insufficiency is a condition marked by the deficiency of exocrine pancreatic enzymes, resulting in maldigestion and nutrient malabsorption. Diagnosis often involves specialized tests such as blood, stool, and pancreatic function assessments, as symptoms are frequently under-detected. In 2025, the market was valued at USD 2.43 billion, projected to grow to USD 2.55 billion in 2026, and expected to reach USD 3.51 billion by 2034, reflecting a CAGR of 4.06% from 2026 to 2034. North America dominated the market in 2025 with a 3.85% share, supported by high awareness, rapid adoption of advanced therapies, and robust R&D infrastructure.
Market Drivers and Trends
Rising Awareness and Therapeutic Innovations
The growth of the EPI therapeutics market is fueled by increased awareness of the disorder and its impact on overall health. Acute pancreatitis, cystic fibrosis, and pancreatic tumors are major contributors to EPI prevalence. For instance, in October 2019, AzurRx BioPharma dosed patients with MS1819-SD, an innovative therapeutic for EPI. The rising recognition of EPI has propelled the development and adoption of therapies such as Pancreatic Enzyme Replacement Therapy (PERT), which remains the conventional and most effective treatment.
Increasing Prevalence of Associated Disorders
The prevalence of gastrointestinal and pancreatic disorders, including autoimmune pancreatitis and Shwachman-Diamond syndrome, directly influences EPI incidence. This has led to continued R&D innovation in therapeutics, enhancing efficacy and safety profiles, which drives market expansion globally.
Technological and Clinical Advancements
Advancements in diagnostic tools and treatment regimens, coupled with rising R&D investments, have facilitated improved therapeutic options. PERT, projected to generate USD 2.12 billion in revenue by 2025, dominates the market due to its efficiency, potency, and established clinical outcomes.
Market Segmentation
By Therapy
- Pancreatic Enzyme Replacement Therapy (PERT): Dominates the market, growing at the highest CAGR due to its clinical effectiveness and broad adoption.
- Nutritional Therapy: Supports patient management but holds a smaller share and lower growth rate. Poor nutrition in EPI patients can lead to increased complications and mortality, highlighting the importance of this segment.
By Distribution Channel
- Hospital Pharmacies: Expected to hold the largest share (67.9% in 2025) as prescriptions are typically issued after clinical diagnosis.
- Retail Pharmacies & Drug Stores: Offer convenience and increasing online pharmacy integration, supporting secondary growth.
Regional Analysis
North America dominated the market with USD 1.89 billion in 2025, rising to USD 1.98 billion in 2026, driven by strong R&D, high treatment adoption, and increasing disease awareness. The U.S. market alone is projected to reach USD 1.69 billion by 2026.
Asia Pacific is poised for the fastest growth due to increasing disposable incomes, adoption of advanced therapeutics, and better awareness. Key markets include Japan (USD 0.09 billion in 2026), China (USD 0.06 billion in 2026), and India (USD 0.03 billion in 2026).
Europe is growing steadily with opportunities in under-penetrated regions. Countries such as the U.K. (USD 0.05 billion in 2026) and Germany (USD 0.07 billion in 2026) are expanding due to rising awareness and improved therapeutic access.
Latin America and Middle East & Africa are expected to experience moderate growth due to under-penetration and emerging healthcare infrastructure.
Competitive Landscape
The market is concentrated with major players such as AbbVie Inc., Janssen Pharmaceuticals, and Allergan, leveraging broad product portfolios and global presence. Smaller and emerging players, including AzurRx and CHIESI Farmaceutici S.p.A., contribute through innovation and new therapeutic pipelines. AbbVie's 2024 gastroenterology portfolio update at the ECCO Congress highlights ongoing R&D commitment to EPI and related disorders.
Conclusion
The global exocrine pancreatic insufficiency therapeutics market is set to expand from USD 2.43 billion in 2025 to USD 3.51 billion by 2034, at a CAGR of 4.06%. Market growth is primarily driven by increasing prevalence of associated disorders, rising awareness, innovations in therapeutics such as PERT, and robust R&D investments. North America remains the dominant region, while Asia Pacific offers the fastest growth potential due to rising healthcare adoption and disposable incomes. Despite challenges like under-penetration in certain regions and ongoing regulatory requirements, the EPI therapeutics market is positioned for sustained growth over the forecast period.
Segmentation By Therapy
- Pancreatic Enzyme Replacement Therapy (PERT)
- Creon
- Zenpep
- Others
- Nutritional Therapy
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies & Drug Stores
- Others
By Geography
- North America (U.S. and Canada)
- Europe (U.K., Germany, France, Italy, Spain, and Rest of Europe)
- Asia Pacific (Japan, China, India, Australia, and Rest of Asia Pacific)
- Rest of the World
Table of Content
1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics
- 3.1. Market Drivers
- 3.2. Market Restraints
- 3.3. Market Opportunities
4. Key Insights
- 4.1. Prevalence of Major Disorders Associated With Exocrine Pancreatic Insufficiency
- 4.2. Pipeline Analysis
- 4.3. Recent Industry Developments Such as Mergers, Partnerships & Acquisitions
- 4.4. Regulatory Scenario
- 4.5. New Product Launches
5. Global Exocrine Pancreatic Insufficiency Therapeutics Market Analysis, Insights and Forecast, 2021-2034
- 5.1. Key Findings / Summary
- 5.2. Market Analysis, Insights and Forecast - By Therapy
- 5.2.1. Pancreatic Enzyme Replacement Therapy (PERT)
- 5.2.1.1. Creon
- 5.2.1.2. Zenpep
- 5.2.1.3. Others
- 5.2.2. Nutritional Therapy
- 5.2.1. Pancreatic Enzyme Replacement Therapy (PERT)
- 5.3. Market Analysis, Insights and Forecast - By Distribution Channel
- 5.3.1. Hospital Pharmacies
- 5.3.2. Retail Pharmacies & Drug Stores
- 5.3.3. Others
- 5.4. Market Analysis, Insights and Forecast - By Country
- 5.4.1. North America
- 5.4.2. Europe
- 5.4.3. Asia Pacific
- 5.4.4. Rest of the World
6. North America Exocrine Pancreatic Insufficiency Therapeutics Market Analysis, Insights and Forecast, 2021-2034
- 6.1. Key Findings / Summary
- 6.2. Market Analysis - By Therapy
- 6.2.1. Pancreatic Enzyme Replacement Therapy (PERT)
- 6.2.1.1. Creon
- 6.2.1.2. Zenpep
- 6.2.1.3. Others
- 6.2.2. Nutritional Therapy
- 6.2.1. Pancreatic Enzyme Replacement Therapy (PERT)
- 6.3. Market Analysis - By Distribution Channel
- 6.3.1. Hospital Pharmacies
- 6.3.2. Retail Pharmacies & Drug Stores
- 6.3.3. Others
- 6.4. Market Analysis - By Country
- 6.4.1. U.S.
- 6.4.2. Canada
7. Europe Exocrine Pancreatic Insufficiency Therapeutics Market Analysis, Insights and Forecast, 2021-2034
- 7.1. Key Findings / Summary
- 7.2. Market Analysis - By Therapy
- 7.2.1. Pancreatic Enzyme Replacement Therapy (PERT)
- 7.2.1.1. Creon
- 7.2.1.2. Zenpep
- 7.2.1.3. Others
- 7.2.2. Nutritional Therapy
- 7.2.1. Pancreatic Enzyme Replacement Therapy (PERT)
- 7.3. Market Analysis - By Distribution Channel
- 7.3.1. Hospital Pharmacies
- 7.3.2. Retail Pharmacies & Drug Stores
- 7.3.3. Others
- 7.4. Market Analysis - By Country
- 7.4.1. U.K.
- 7.4.2. Germany
- 7.4.3. France
- 7.4.4. Spain
- 7.4.5. Italy
- 7.4.6. Rest of Europe
8. Asia Pacific Exocrine Pancreatic Insufficiency Therapeutics Market Analysis, Insights and Forecast, 2021-2034
- 8.1. Key Findings / Summary
- 8.2. Market Analysis - By Therapy
- 8.2.1. Pancreatic Enzyme Replacement Therapy (PERT)
- 8.2.1.1. Creon
- 8.2.1.2. Zenpep
- 8.2.1.3. Others
- 8.2.2. Nutritional Therapy
- 8.2.1. Pancreatic Enzyme Replacement Therapy (PERT)
- 8.3. Market Analysis - By Distribution Channel
- 8.3.1. Hospital Pharmacies
- 8.3.2. Retail Pharmacies & Drug Stores
- 8.3.3. Others
- 8.4. Market Analysis - By Country
- 8.4.1. Japan
- 8.4.2. China
- 8.4.3. India
- 8.4.4. Australia
- 8.4.5. Rest of Asia Pacific
9. Rest of the World Exocrine Pancreatic Insufficiency Therapeutics Market Analysis, Insights and Forecast, 2021-2034
- 9.1. Key Findings / Summary
- 9.2. Market Analysis - By Therapy
- 9.2.1. Pancreatic Enzyme Replacement Therapy (PERT)
- 9.2.1.1. Creon
- 9.2.1.2. Zenpep
- 9.2.1.3. Others
- 9.2.2. Nutritional Therapy
- 9.2.1. Pancreatic Enzyme Replacement Therapy (PERT)
- 9.3. Market Analysis - By Distribution Channel
- 9.3.1. Hospital Pharmacies
- 9.3.2. Retail Pharmacies & Drug Stores
- 9.3.3. Others
- 9.4. Market Analysis - By Country
10. Competitive Analysis
- 10.1. Key Industry Developments
- 10.2. Global Market Share Analysis (2025)
- 10.3. Competition Dashboard
- 10.4. Comparative Analysis - Major Players
- 10.5. Company Profiles
- 10.5.1. AbbVie Inc.
- 10.5.1.1. Overview,
- 10.5.1.2. Products & services,
- 10.5.1.3. SWOT analysis,
- 10.5.1.4. Recent developments,
- 10.5.1.5. strategies,
- 10.5.1.6. financials (based on availability)
- 10.5.2. Janssen Pharmaceuticals, Inc.
- 10.5.2.1. Overview,
- 10.5.2.2. Products & services,
- 10.5.2.3. SWOT analysis,
- 10.5.2.4. Recent developments,
- 10.5.2.5. strategies,
- 10.5.2.6. financials (based on availability)
- 10.5.3. Allergan
- 10.5.3.1. Overview,
- 10.5.3.2. Products & services,
- 10.5.3.3. SWOT analysis,
- 10.5.3.4. Recent developments,
- 10.5.3.5. strategies,
- 10.5.3.6. financials (based on availability)
- 10.5.4. AzurRx
- 10.5.4.1. Overview,
- 10.5.4.2. Products & services,
- 10.5.4.3. SWOT analysis,
- 10.5.4.4. Recent developments,
- 10.5.4.5. strategies,
- 10.5.4.6. financials (based on availability)
- 10.5.5. CHIESI Farmaceutici S.p.A.
- 10.5.5.1. Overview,
- 10.5.5.2. Products & services,
- 10.5.5.3. SWOT analysis,
- 10.5.5.4. Recent developments,
- 10.5.5.5. strategies,
- 10.5.5.6. financials (based on availability)
- 10.5.6. Other Prominent Players
- 10.5.6.1. Overview,
- 10.5.6.2. Products & services,
- 10.5.6.3. SWOT analysis,
- 10.5.6.4. Recent developments,
- 10.5.6.5. strategies,
- 10.5.6.6. financials (based on availability)
- 10.5.1. AbbVie Inc.
List of Tables
- Table 1: Global Exocrine Pancreatic Insufficiency Therapeutics Market Revenue (US$ Mn) Forecast, by Product, 2021-2034
- Table 2: Global Exocrine Pancreatic Insufficiency Therapeutics Market Revenue (US$ Mn) Forecast, by Pancreatic Enzyme Replacement Therapy (PERT), 2021-2034
- Table 3: Global Exocrine Pancreatic Insufficiency Therapeutics Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2021-2034
- Table 4: Global Exocrine Pancreatic Insufficiency Therapeutics Market Revenue (US$ Mn) Forecast, by Region, 2021-2034
- Table 5: North America Exocrine Pancreatic Insufficiency Therapeutics Market Revenue (US$ Mn) Forecast, by Product, 2021-2034
- Table 6: North America Exocrine Pancreatic Insufficiency Therapeutics Market Revenue (US$ Mn) Forecast, by Pancreatic Enzyme Replacement Therapy (PERT), 2021-2034
- Table 7: North America Exocrine Pancreatic Insufficiency Therapeutics Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2021-2034
- Table 8: North America Exocrine Pancreatic Insufficiency Therapeutics Market Revenue (US$ Mn) Forecast, By Country, 2021-2034
- Table 9: Europe Exocrine Pancreatic Insufficiency Therapeutics Market Revenue (US$ Mn) Forecast, by Product, 2021-2034
- Table 10: Europe Exocrine Pancreatic Insufficiency Therapeutics Market Revenue (US$ Mn) Forecast, by Pancreatic Enzyme Replacement Therapy (PERT), 2021-2034
- Table 11: Europe Exocrine Pancreatic Insufficiency Therapeutics Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2021-2034
- Table 12: Europe Exocrine Pancreatic Insufficiency Therapeutics Market Revenue (US$ Mn) Forecast, By Country/ Sub-region, 2021-2034
- Table 13: Asia Pacific Exocrine Pancreatic Insufficiency Therapeutics Market Revenue (US$ Mn) Forecast, by Product, 2021-2034
- Table 14: Asia Pacific Exocrine Pancreatic Insufficiency Therapeutics Market Revenue (US$ Mn) Forecast, by Pancreatic Enzyme Replacement Therapy (PERT), 2021-2034
- Table 15: Asia Pacific Exocrine Pancreatic Insufficiency Therapeutics Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2021-2034
- Table 16: Asia Pacific Exocrine Pancreatic Insufficiency Therapeutics Market Revenue (US$ Mn) Forecast, By Country/ Sub-region, 2021-2034
- Table 17: Rest of the World Exocrine Pancreatic Insufficiency Therapeutics Market Revenue (US$ Mn) Forecast, by Product, 2021-2034
- Table 18: Rest of the World Exocrine Pancreatic Insufficiency Therapeutics Market Revenue (US$ Mn) Forecast, by Pancreatic Enzyme Replacement Therapy (PERT), 2021-2034
- Table 19: Rest of the World Exocrine Pancreatic Insufficiency Therapeutics Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2021-2034
- Table 20: Rest of the World Exocrine Pancreatic Insufficiency Therapeutics Market Revenue (US$ Mn) Forecast, By Country/ Sub-region, 2021-2034
List of Figures
- Figure 1: Global Exocrine Pancreatic Insufficiency Therapeutics Market Revenue Breakdown (US$ Mn, %) by Region, 2025 & 2034
- Figure 2: Global Exocrine Pancreatic Insufficiency Therapeutics Market Value Share (%), by Product, 2025 & 2034
- Figure 3: Global Exocrine Pancreatic Insufficiency Therapeutics Market Forecast (US$ Mn), by Pancreatic Enzyme Replacement Therapy (PERT), 2021-2034
- Figure 4: Global Exocrine Pancreatic Insufficiency Therapeutics Market Forecast (US$ Mn), by Nutritional Therapy, 2021-2034
- Figure 5: Global Exocrine Pancreatic Insufficiency Therapeutics Market Value Share (%), by Distribution Channel, 2025 & 2034
- Figure 6: Global Exocrine Pancreatic Insufficiency Therapeutics Market Forecast (US$ Mn), by Hospital Pharmacies, 2021-2034
- Figure 7: Global Exocrine Pancreatic Insufficiency Therapeutics Market Forecast (US$ Mn), by Retail Pharmacies & Drug Stores, 2021-2034
- Figure 8: Global Exocrine Pancreatic Insufficiency Therapeutics Market Forecast (US$ Mn), by Others, 2021-2034
- Figure 9: Global Exocrine Pancreatic Insufficiency Therapeutics Market Value (US$ Mn), by Region, 2025 & 2034
- Figure 10: North America Exocrine Pancreatic Insufficiency Therapeutics Market Value (US$ Mn), by Product, 2025 & 2034
- Figure 11: North America Exocrine Pancreatic Insufficiency Therapeutics Market Value Share (%), by Product, 2025
- Figure 12: North America Exocrine Pancreatic Insufficiency Therapeutics Market Value (US$ Mn), by Distribution Channel, 2025 & 2034
- Figure 13: North America Exocrine Pancreatic Insufficiency Therapeutics Market Value Share (%), by Distribution Channel, 2025
- Figure 14: North America Exocrine Pancreatic Insufficiency Therapeutics Market Value (US$ Mn), By Country, 2025 & 2034
- Figure 15: North America Exocrine Pancreatic Insufficiency Therapeutics Market Value Share (%), By Country, 2025
- Figure 16: Europe Exocrine Pancreatic Insufficiency Therapeutics Market Value (US$ Mn), by Product, 2025 & 2034
- Figure 17: Europe Exocrine Pancreatic Insufficiency Therapeutics Market Value Share (%), by Product, 2025
- Figure 18: Europe Exocrine Pancreatic Insufficiency Therapeutics Market Value (US$ Mn), by Distribution Channel, 2025 & 2034
- Figure 19: Europe Exocrine Pancreatic Insufficiency Therapeutics Market Value Share (%), by Distribution Channel, 2025
- Figure 20: Europe Exocrine Pancreatic Insufficiency Therapeutics Market Value (US$ Mn), By Country/ Sub-region, 2025 & 2034
- Figure 21: Europe Exocrine Pancreatic Insufficiency Therapeutics Market Value Share (%), By Country/ Sub-region, 2025
- Figure 22: Asia Pacific Exocrine Pancreatic Insufficiency Therapeutics Market Value (US$ Mn), by Product, 2025 & 2034
- Figure 23: Asia Pacific Exocrine Pancreatic Insufficiency Therapeutics Market Value Share (%), by Product, 2025
- Figure 24: Asia Pacific Exocrine Pancreatic Insufficiency Therapeutics Market Value (US$ Mn), by Distribution Channel, 2025 & 2034
- Figure 25: Asia Pacific Exocrine Pancreatic Insufficiency Therapeutics Market Value Share (%), by Distribution Channel, 2025
- Figure 26: Asia Pacific Exocrine Pancreatic Insufficiency Therapeutics Market Value (US$ Mn), By Country/ Sub-region, 2025 & 2034
- Figure 27: Asia Pacific Exocrine Pancreatic Insufficiency Therapeutics Market Value Share (%), By Country/ Sub-region, 2025
- Figure 28: Rest of the World Exocrine Pancreatic Insufficiency Therapeutics Market Value (US$ Mn), by Product, 2025 & 2034
- Figure 29: Rest of the World Exocrine Pancreatic Insufficiency Therapeutics Market Value Share (%), by Product, 2025
- Figure 30: Rest of the World Exocrine Pancreatic Insufficiency Therapeutics Market Value (US$ Mn), by Distribution Channel, 2025 & 2034
- Figure 31: Rest of the World Exocrine Pancreatic Insufficiency Therapeutics Market Value Share (%), by Distribution Channel, 2025
- Figure 32: Global Exocrine Pancreatic Insufficiency Therapeutics Market Share (%), By Company, 2025
